Menu Search
Equities

Alphamab Oncology

3NK:STU

Alphamab Oncology

Actions
  • Price (EUR)0.530
  • Today's Change0.005 / 0.95%
  • Shares traded0.00
  • 1 Year change-63.45%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in CNYView more

In 2023, Alphamab Oncology did not generate a significant amount of cash. Cash Flow from Financing totalled 218.07m or 99.68% of revenues. In addition the company used 202.84m for operations while cash used for investing totalled 18.11m.
Cash flow per share-0.1585
Price/Cash flow per share--
Book value per share1.82
Tangible book value per share1.82
More ▼

Balance sheet in CNYView more

Alphamab Oncology appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.25% of the market capitalization can be attributed to its 1.09bn and debt could be paid in full if management chose.
Current ratio4.61
Quick ratio4.42
Total debt/total equity0.2005
Total debt/total capital0.167
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.